nab-paclitaxel; gemcitabine

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

First-line Treatment of Advanced Pancreatic CancerFirst-line Treatment of Metastatic Pancreatic Cancer

Phase 3

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

RecruitingNCT05751850

Jiangsu HengRui Medicine Co., Ltd.First-line Treatment of Advanced Pancreatic Cancer

Start: 2023-06-13End: 2025-12-30Target: 778Updated: 2024-05-09

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

RecruitingNCT07238283

Jiangsu HengRui Medicine Co., Ltd.First-line Treatment of Metastatic Pancreatic Cancer

Start: 2025-12-02End: 2028-12-31Target: 662Updated: 2025-12-09